Trial Profile

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HB 0045 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Ductal carcinoma; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Sarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Huaota Biopharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com